Black Owned Wellness Company, Pretty Spirits Crowdfunds to Open First Retail Location
CALABASAS, Calif., March 10, 2023 (GLOBE NEWSWIRE) -- Christine Deloatch and Lauren Brewer, owners and co-founders of PrettySpirits.com, an online spiritual wellness shop, have launched a crowdfunding campaign to open their first retail location in Calabasas, California. The initiative aims to raise $50,000 to cover costs associated with maintaining their storefront. Donations will help the Black, female-owned business with a heartfelt mission to improve the world.
Pretty Spirits has been fulfilling its mission to offer products and services that enhance self-awareness and help customers better manage anxiety, stress, and depression for the last seven years. In 2015, they began by offering services such as psychic readings and reiki healing to help clients break through tough emotional challenges connected to various traumas. As their client base grew, they developed their first oracle deck as a tool for self-discovery. They have since expanded their product line to include hundreds of spiritual and wellness products.
Donations will allow Pretty Spirits to continue to provide mindful products, resources, and services to those who suffer from emotional struggles like anxiety, abandonment and low self-esteem. The campaign goal amount of $50,000 will cover the rent and inventory storage for one year, store furnishings, the POS system, signage, marketing, inventory, and maker materials. Every dollar counts, and the campaign is grateful for any amount given towards meeting its goal.
The new physical location in Calabasas, California, is a suite in Bungalow 21, a first-of-its-kind, family-owned business and wellness center. Pretty Spirits will begin their permanent residency in a modest space on April 16th, 2023. The founders are excited to showcase their mindfully curated products and provide their healing services.
Christine Deloatch and Lauren Brewer are mompreneurs who set out to impact the world significantly. Their mission is to create a safe space for millions seeking the knowledge and tools to align with higher self-worth, greater fulfillment, and inner peace. Donations from caring people like you help Pretty Spirits achieve its mission and improve the world.
To donate to Pretty Spirits' crowdfunding campaign, visit their donation page: https://prettyspirits.com/pages/donate-to-pretty-spirits.
Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/eeee80c5-694c-47a6-8a4a-da24f45569a6
https://www.globenewswire.com/NewsRoom/AttachmentNg/70717139-52d6-4381-b00d-badbe1d241d8
https://www.globenewswire.com/NewsRoom/AttachmentNg/122a2744-65bb-4504-ba30-a27590fb4508
For more information, please contact
Joseph Benjamin
+1 323 659 0553
jbenjamin@prophecybrand.com
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
TRESU Investment Holding A/S – Registration for investor call28.3.2023 11:04:29 CEST | Press release
TRESU INVESTMENT HOLDING A/S ANNOUNCEMENT NO. 02.2023 28.03.2022 TRESU Investment Holding A/S is pleased to invite you to the financial results call, which is being held: Wednesday, 5 April 2022, at 11am CET. The Annual Report will be presented by Christian Jacob Flarup, CEO and Torben Børsting, CFO. After the presentation there will be an opportunity for Q+A. A recording of the results call will be made available for four hours on the TRESU IR website. To register for the investor call, please send an e-mail to Financial manager at TRESU A/S Finn Holm no later than 4 April 2023 9am CET - fho@tresu.com Christian Jacob Flarup CEO, TRESU For further details, please contact: CEO, Christian Jacob Flarup, phone: +45 2027 7971 CFO, Torben Børsting, phone: +45 5130 2780 Attachment Quarterly reporting - Call - 2022 Q4
Alvotech Provides Update on Corporate Sustainability Framework28.3.2023 11:00:00 CEST | Press release
Alvotech (Nasdaq: ALVO) (the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced an update to the Company’s Corporate Sustainability framework, including the release of key environmental, social and governance (“ESG”) indicators for 2022. “As part of our commitment to improve the sustainability of healthcare by providing access to more affordable biologic medicines, we recognize that corporate sustainability is closely linked to our long-term success and the value we may bring to patients, healthcare providers and all of our stakeholders,” said Robert Wessman, Founder, Chairman and CEO of Alvotech. Data on key ESG indicators for 2020-2022 can be found on Alvotech’s dedicated web portal. Alvotech’s Board of Directors has established a Corporate Sustainability Committee (CSC) to oversee the Company’s strategy as it relates to ESG matters. Alvotech’s corporate headquarters, purpose-built manuf
Zealand Pharma Announces Positive Phase 1 Clinical Results with Amylin Analogue ZP839628.3.2023 10:54:21 CEST | Press release
Company announcement – No. 7 / 2023 Zealand Pharma Announces Positive Phase 1 Clinical Results with Amylin Analogue ZP8396 Dose-dependent body weight reductions of up to a mean of 4.2% from baseline (4.8% placebo corrected) following a single dose of ZP8396In development as a non-incretin peptide therapyfor the potential management of overweight and obesity Copenhagen, Denmark, March 28, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) (CVR-no. 20045078) a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced Phase 1a results for ZP8396, the company’s amylin analogue. The first-in-human study was designed to assess safety, pharmacokinetic (PK) and pharmacodynamic effects of ZP8396 in healthy lean and overweight people. “We are excited by the potential of amylin as an alternative, non-incretin treatment for overweight and obesity, and are very encouraged that treatment with a single dose of ZP8396 led to meaningful dose
Indkaldelse til ordinær generalforsamling i SKAKO A/S28.3.2023 10:50:52 CEST | pressemeddelelse
Til NASDAQ OMX Copenhagen A/S GlobeNewswire Faaborg, den 28. marts 2023 Selskabsmeddelelse nr. 5/2023 Indkaldelse til ordinær generalforsamling i SKAKO A/S SKAKO A/S indkalder til ordinær generalforsamling i selskabet til afholdelse onsdag den 19. april 2023, kl. 15.00 på selskabets adresse. Indkaldelsen er sket jf. selskabets vedtægter § 7 og er tilgængelig på selskabets hjemmeside. Udbytte På baggrund af det stærke resultat i 2022 og kapitalstrukturen i SKAKO A/S pr. 31. december 2022 anbefaler bestyrelsen en udbytteudlodning på DKK 5 pr. aktie svarende til 61,0% af årets resultat og en samlet udbytteudlodning på DKK 15,4 mio. Med en aktiekurs på 62,6 kr. pr. 31. december 2022 svarer det til en udbytteprocent på 8,0%. Udbyttebetalingen vil være et behandlingspunkt på agendaen for den ordinære generalforsamling 19. april 2023. Ex-udbytte dato: 19. april 2023 Optagelsesdato: 20. april 2023 Udbetalingsdato: 24. april 2023 Med venlig hilsen SKAKO A/S Jens Wittrup Willumsen Bestyrelsesfor
Aalborg Boldspilklub A/S indkalder til ordinær generalforsamling28.3.2023 10:50:49 CEST | pressemeddelelse
NASDAQ Copenhagen A/S Børsmeddelelse nr. 2023/06 Aalborg, 28. marts 2023 Vedhæftet indkaldelse og dagsorden til ordinær generalforsamling i Aalborg Boldspilklub A/S onsdag 19. april 2023 kl. 16.00 på Aalborg Portland Park. Venlig hilsen Aalborg Boldspilklub A/S Thomas Bælum Administrerende direktør For yderligere oplysninger: Thomas Bælum 2251 7901 Vedhæftede filer Dagsorden 2023 - Inkl Bilag A og Bilag BAAB_ Brevstemme blanket_GF2023_v5